NASDAQ:XBIT - XBiotech Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.13 -0.07 (-1.67 %) (As of 11/19/2018 07:13 AM ET)Previous Close$4.20Today's Range$4.06 - $4.2252-Week Range$2.13 - $5.80Volume19,227 shsAverage Volume32,251 shsMarket Capitalization$147.94 millionP/E RatioN/ADividend YieldN/ABeta0.04 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas. Receive XBIT News and Ratings via Email Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XBIT Previous Symbol CUSIPN/A Webwww.xbiotech.com Phone512-386-2900 Debt Debt-to-Equity RatioN/A Current Ratio9.26 Quick Ratio9.26 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$1.31 per share Price / Book3.15 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-33,150,000.00 Net MarginsN/A Return on Equity-41.44% Return on Assets-39.54% Miscellaneous Employees51 Outstanding Shares35,820,000Market Cap$147.94 million OptionableOptionable XBiotech (NASDAQ:XBIT) Frequently Asked Questions What is XBiotech's stock symbol? XBiotech trades on the NASDAQ under the ticker symbol "XBIT." When is XBiotech's next earnings date? XBiotech is scheduled to release their next quarterly earnings announcement on Friday, March 15th 2019. View Earnings Estimates for XBiotech. Has XBiotech been receiving favorable news coverage? News coverage about XBIT stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. XBiotech earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days. Who are some of XBiotech's key competitors? Some companies that are related to XBiotech include Collegium Pharmaceutical (COLL), CymaBay Therapeutics (CBAY), Rocket Pharmaceuticals (RCKT), Ra Pharmaceuticals (RARX), Basilea Pharmaceutica (BPMUF), Arvinas (ARVN), Insys Therapeutics (INSY), Eidos Therapeutics (EIDX), Arcus Biosciences (RCUS), GlycoMimetics (GLYC), ChemoCentryx (CCXI), Innate Pharma (IPHYF), Clementia Pharmaceuticals (CMTA), Kezar Life Sciences (KZR) and Beyondspring (BYSI). Who are XBiotech's key executives? XBiotech's management team includes the folowing people: Mr. John Simard, Founder, Pres, CEO & Chairman (Age 56)Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 40)Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 51)Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 62)Ms. Norma I. Gonzalez, VP of Quality (Age 61) When did XBiotech IPO? (XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO. How do I buy shares of XBiotech? Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is XBiotech's stock price today? One share of XBIT stock can currently be purchased for approximately $4.13. How big of a company is XBiotech? XBiotech has a market capitalization of $147.94 million. XBiotech employs 51 workers across the globe. What is XBiotech's official website? The official website for XBiotech is http://www.xbiotech.com. How can I contact XBiotech? XBiotech's mailing address is 5217 WINNEBAGO LN, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected] MarketBeat Community Rating for XBiotech (NASDAQ XBIT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 141 (Vote Outperform)Underperform Votes: 128 (Vote Underperform)Total Votes: 269MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe XBIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/19/2018 by MarketBeat.com StaffFeatured Article: What does cost of debt say about a company’s financial health?